| Assay ID | Title | Year | Journal | Article |
|---|
| AID758855 | Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7.5 cells after 3 days by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
| Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID774052 | Antiviral activity against Hepatitis C virus 1b RO-1 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366905 | Metabolic stability in human hepatocytes assessed as compound remaining after 4 hrs | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366916 | Bioavailability in Sprague-Dawley rat at 2 mg/kg, po and 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774060 | Antiviral activity against Hepatitis C virus 1a RO-28 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774047 | Antiviral activity against Hepatitis C virus 1b RO-8 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366908 | Inhibition of CYP3A4 | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366904 | Cytotoxicity against HCV 1b Con1 isolate infected human Huh7.5 cells assessed as renilla luciferase activity after 3 days by RNA replicon assay | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366914 | Half life in Sprague-Dawley rat at 2 mg/kg, po and 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774057 | Antiviral activity against Hepatitis C virus 1a RO-34 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774061 | Antiviral activity against Hepatitis C virus 1a RO-24 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774058 | Antiviral activity against Hepatitis C virus 1a RO-33 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID650854 | Antiviral activity against Hepatitis C virus genotype 1b 1389 infected in human HuH5.2 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay | 2012 | Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
| Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. |
| AID774063 | Antiviral activity against Hepatitis C virus 1a RO-18 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366907 | Inhibition of CYP2C8 | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366920 | Tmax in Beagle dog at 2 mg/kg, po and 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774045 | Antiviral activity against Hepatitis C virus 1b RO-10 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366913 | Hepatic clearance in rat liver microsomes | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID758854 | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7.5 cells after 3 days by luciferase reporter gene assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
| Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. |
| AID774054 | Antiviral activity against Hepatitis C virus 1a RO-41 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366922 | Plasma clearance in cynomolgus monkey at 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366899 | Volume of distribution at steady state in Sprague-Dawley rat at 2 mg/kg, po and 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366921 | Bioavailability in Beagle dog at 2 mg/kg, po and 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366903 | Antiviral activity against HCV 1b Con1 isolate in human Huh7.5 cells assessed as renilla luciferase activity after 3 days by RNA replicon assay | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366912 | Hepatic clearance in monkey liver microsomes | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366909 | Inhibition of CYP2C9 | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774059 | Antiviral activity against Hepatitis C virus 1a RO-32 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366900 | Plasma clearance in Sprague-Dawley rat at 2 mg/kg, po and 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366902 | Inhibition of HCV 1b isolate BK NS5B Cdelta21 polymerase | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366911 | Aqueous solubility of compound at pH 6.2 | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366924 | Half life in cynomolgus monkey at 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366923 | Volume of distribution at steady state in cynomolgus monkey at 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774048 | Antiviral activity against Hepatitis C virus 1b RO-7 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774055 | Antiviral activity against Hepatitis C virus 1a RO-38 expressing NS5B S556G mutant assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774062 | Antiviral activity against Hepatitis C virus 1a RO-22 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366906 | Inhibition of CYP1A2 | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774053 | Antiviral activity against Hepatitis C virus Con1 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366910 | Inhibition of CYP2C19 | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366915 | Tmax in Sprague-Dawley rat at 2 mg/kg, po and 2 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774064 | Antiviral activity against Hepatitis C virus isolate H77 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774046 | Antiviral activity against Hepatitis C virus 1b RO-9 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366919 | Half life in Beagle dog at 2 mg/kg, po and 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774056 | Antiviral activity against Hepatitis C virus 1a RO-35 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID774051 | Antiviral activity against Hepatitis C virus 1b RO-2 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366917 | Plasma clearance in Beagle dog at 2 mg/kg, po and 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID366901 | Inhibition of CYP2D6 in human liver microsomes | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774050 | Antiviral activity against Hepatitis C virus 1b RO-3 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID366918 | Volume of distribution at steady state in Beagle dog at 2 mg/kg, po and 1 mg/kg, iv | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| AID774049 | Antiviral activity against Hepatitis C virus 1b RO-4 expressing NS5B assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
| Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. |
| AID1070899 | Antiviral activity against HCV genotype 1 infected in human patient assessed as log10 reduction in viral RNA in plasma at 700 mg/kg, bid after 8 days | 2014 | Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
| Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infection. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2009 | Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
| Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |